128811-31-4

Basic information

• Product Name: (2R)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER
• Synonyms: (2R)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER;D-1-BOC-O-TBDMS-PYROGLUTAMINOL
• CAS NO: 128811-31-4
• Molecular Formula: C₁₆H₃₁NO₄Si
• Molecular Weight: 329.51
• Mol File: 128811-31-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2R)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER(128811-31-4)
• EPA Substance Registry System: (2R)-2-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-5-OXO-1-PYRROLIDINECARBOXYLATE-1,1-DIMETHYLETHYL ESTER(128811-31-4)

Safety Data

• Hazardous Substances Data: 128811-31-4(Hazardous Substances Data)

Upstream product

• 13515-99-6 D-glutamic acid dimethyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1244958-71-1 C₂₀H₃₃NO₅Si 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 64700-65-8 methyl (2R)-pyroglutamate 
• 6893-26-1 D-Glutamic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 185303-67-7 (R)-N-(tert-butoxycarbonyl)-5-formylpyrrolidin-2-one 
• 141293-21-2 (1'S,4''R,5R)-1-(tert-butoxycarbonyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)hydroxymethyl]pyrrolidin-2-one 
• 141293-15-4 (1'S,2R,4''R)-2-[(2,2-dimethyl-[1,3]dioxolan-4-yl)hydroxymethyl]-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylic acid tert-butyl ester 
• 141293-28-9 N-(tert-butoxycarbonyl)-2-[(tert-butyldimethylsilyl)oxy]pyrrole 
• 141293-14-3 N-(tert-butoxycarbonyl)pyrrol-2(5H)-one 
• 128811-37-0 tert-butyl (2R)-2-(hydroxymethyl)-5-oxopyrrolidine-1-carboxylate 

Downstream Products

• 128811-37-0 tert-butyl (2R)-2-(hydroxymethyl)-5-oxopyrrolidine-1-carboxylate 
• 1266231-72-4 tert-butyl [(1S)-2-{[(1S)-1-cyclohexyl-2-{(1aS,4S,6aR,7aS)-4-[(4R)-3,4-dihydro-2H-chromen-4-ylcarbamoyl]octahydro-5H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazin-5-yl}-2-oxoethyl]amino}-1-methyl-2-oxoethyl]methylcarbamate 
• 1266231-65-5 methyl (1aS,4S,6aR,7aS)-5-benzyloctahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1266231-39-3 1-[(1R,3R,5R)-2-azabicyclo[3.1.0]hex-3-yl]-N-benzylmethanamine 
• 1452400-41-7 methyl (1aR,4R,6aR,7aR)-5-benzyloctahydro-1H-cyclopropa[4,5] pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1452400-42-8 methyl (1aS,4R,6aR,7aS)-5-benzyloctahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1266231-40-6 methyl (1aR,4S,6aR,7aR)-5-benzyloctahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-4-carboxylate 
• 1266231-63-3 tert-butyl (1S,3R,5S)-3-[(benzylamino)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1266231-37-1 tert-butyl (1R,3R,5R)-3-[(benzylamino)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1266323-49-2 1-[(1S,3R,5S)-2-azabicyclo[3.1.0]hex-3-yl]-N-benzylmethanamine 
• 1369917-75-8 methyl 4-(1-{2-[(2R)-2-{(1E,3S)-3-(tert-butyldimethylsilyloxy)-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]ethyl}cyclopropyl)butanoate 
• 1369917-74-7 methyl (5R)-7-[(2R)-2-{(1E,3S)-3-(tert-butyldimethylsilyloxy)-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]-5-methylheptanoate 
• 1369917-72-5 methyl (5S)-7-[(2R)-2-{(1E,3S)-3-(tert-butyldimethylsilyloxy)-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]-5-methylheptanoate 
• 1369917-65-6 (5R)-5-{(1E,3S)-3-(tert-butyldimethylsilyloxy)-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl}-2-pyrrolidinone 

Relevant articles and documents

Total syntheses of N-boc-protected 3′-deoxy-4′-azathymidine and 4′-azauridine

Novel modified nucleosides 4, 11, ent-11, and 17, wherein the furanose ring oxygen is replaced by nitrogen, have been synthesized by reacting azasugars 3, 10, ent-10, and 15 with silylated uracil or thymine bases.

NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5- hydroxytryptamine receptor 7 activity. A is selected

Asymmetric synthesis of ceramide sphingolipid based on (2S,3S,4S)-3,4- dihydroxy-5-(hydroxymethyl)pyrrolidine lactam

A facile approach to the versatile chiral building block 2 was developed based on glutamic acid, whereby a new method for asymmetric synthesis of sex pheromone 1 was explored from cheap glutamic acid.